Company intelligence / Profile preview
Cognition Therapeutics, Inc.
Purchase, New York, United Statescogrx.com ↗
- Ownership
- Public · CGTX
- Employees
- ~28
- Development stage
- Phase 2
01
Overview
Zervimesine (CT1812) showed positive results in Phase 2 SHIMMER study for DLB with improvements across measures of behavior, function, cognition and movement. In the Phase 2 SHINE study for Alzheimer's disease, results showed a 39% slowing of decline favoring CT1812, though the 1.04-point difference between placebo and treatment groups was modest. The company is advancing zervimesine into late-stage clinical trials for both DLB and AD in 2025.
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Small moleculesOral therapeutics
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Alzheimer's Clinical Trials Consortium (ACTC)
04
Financials
- Market cap
- $87.7M
- Total revenue
- $0
- Enterprise value
- $54.2M
Beyond the preview
Go deeper on Cognition Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cognition Therapeutics, Inc..